Thyroid cancers are the most frequent endocrine neoplasms and mutations in the thyrotropin receptor (TSHR) are unusually frequent. Here we present the state-of-the-art concerning the role of TSHR in thyroid cancer and discuss it in light of the cancer stem cell theory or the classical view. We briefly review the gene and protein structure updating the cancer related TSHR database. Intriguingly, hyperfunctioning TSHR mutants characterise differentiated cancers in contrast to undifferentiated thyroid cancers which very often bear silenced TSHR. It remains unclear whether TSHR alterations in thyroid cancers play a role in the onset or they appear as a consequence of genetic instability during evolution, but the presence of functional TSHR is exploited in therapy. We outline the signalling network build up in the thyrocyte between TSHR/PKA and other proliferative pathways such as Wnt, PI3K and MAPK. This network’s integrity surely plays a role in the onset/evolution of thyroid cancer and needs further research. Lastly, future investigation of epigenetic events occurring at the TSHR and other loci may give better clues for molecular based therapy of undifferentiated thyroid carcinomas. Targeted demethylating agents, histone deacetylase inhibitors combined with retinoids and specific RNAs may help treatment in the future.

Keywords: Thyrotropin; Cancer; Signalling; MAPK; PI3K; PKA; Wnt; Thyroid; NIS

Sinalização de TSH e Câncer.
Os cânceres de tiroidé são as neoplasias endócrinas mais frequentes e as mutações no receptor de tirotrofina (TSHR) são incomumente frequentes. Nesta revisão nós apresentamos o “estado da arte” com relação ao papel do TSHR no câncer de tiroidé e o discutimos à luz da teoria da célula matriz do câncer ou a visão clássica. Revisamos brevemente a estrutura do gene e da proteína, atualizando a base de dados das mutações do TSHR relacionadas ao câncer. Curiosamente, mutações do TSHR com hiperfunção caracterizam cânceres diferenciados, em contraste com os cânceres de tiroidé indiferenciados, os quais muito comumente mostram TSHR silenciados. Permanece obscuro se as alterações do TSHR em cânceres de tiroidé têm algum papel no surgimento ou se elas aparecem como conseqüência da instabilidade genética durante seu desenvolvimento, mas a presença de TSHR funcional é explorada na terapia. Nós delineamos a rede de sinalização desenvolvida no tirocito entre TSHR/PKA e outras vias proliferativas como a Wnt, PI3K e MAPK. A integridade desta rede certamente tem um papel no surgimento/evolução do câncer de tiroidé e necessita de novas pesquisas. Finalmente, novas investigações sobre os eventos epigenéticos que ocorrem no TSHR e outros locais poderão trazer novas informações para uma terapia de base molecular nos carcinomas indiferenciados de tiroidé. Agentes demetilantes direcionados, inibidores da histona-deacetilase, combinados com retinóides e RNAs específicos poderão auxiliar no tratamento futuro.

Descritores: Tirotrofina; Câncer; Sinalização; MAPK; PI3K; PKA; Wnt; Tireóide; NIS
THYROID CANCER: THE FREQUENCY, THE TYPES AND THE HYPOTHESIS

Thyroid cancer is the most frequent endocrine neoplasia and represents 1% of all cancers. According to the American Cancer Society, the frequency of thyroid cancer in USA was 100 per million population in 2003, this incidence has been increasing at more than 5%/yr for a decade mostly due to increased diagnosis of small tumours (1). The annual mortality from thyroid cancer in 2003 was 5–6 per million. The discrepancy between incidence and mortality reflects the good prognosis for most thyroid cancers. Thyroid neoplasms may appear as benign nodules and adenomas or malignant tumours that can be from follicular cell origin: differentiated or undifferentiated; from the parafollicular C cells; medullary thyroid carcinoma (MTC), or else. Differentiated carcinomas are histologically divided into papillary thyroid carcinoma (PTC) or follicular thyroid carcinoma (FTC). Detailed descriptions of this classification can be consulted elsewhere, i.e.: http://www.meb.uni-bonn.de/cancer.gov/CDR0000062913.html. Most thyroid tumours are sporadic as a consequence of somatic mutations, although hereditary thyroid carcinoma resulting from germinal mutations also occurs. Currently there are 2 hypotheses to explain thyroid cancer onset that are summarised in figure 1. The classical view, depicted on the right, considers thyroid carcinoma as a complication of a pre-existing follicular adenoma accumulating mutations, which drive the progression through a de-differentiation process. Differentiated thyrocytes

Figure 1. Two hypotheses to explain the onset of thyroid cancers: The Cancer Stem Cell hypothesis is represented on the left side: thyroid cell precursors may encounter mutations that deviates them from the normal differentiation path (vertical arrows) to develop into cancer stem cells (horizontal arrows). Thyroid cell precursors are abbreviated as NCP (Neural Crest Precursor) or FSP (Follicular Cells Precursor) to stress their different origin and characteristics. NCP migrate long distances to populate the thyroid and perhaps retain migrating (invasion) characteristics that enable them to become malignant with a smaller number of mutations. Mutations leading from every precursor to a different type of cancer are depicted on the horizontal arrows and are classified in (i) large chromosomal rearrangements, (ii) gain of function or excessive levels and (iii) silencing or disabling mutations in the proteins described. These mutations would lead from the precursor of a thyroid cell to a cancer cell (either latent or proliferative). The classical hypothesis is represented to the right of the horizontal arrows. This view assumes a process of de-differentiation represented by vertical arrows leading from differentiated thyrocyte at the bottom to the most undifferentiated: the Anaplastic Thyroid Cancer. The mutations described before would correspond now to the vertical arrows leading from one type of cancer to another. The column previous to the last represent the degree of differentiation (D) or undifferentiation (U) together with the aggressiveness of the cancer, which will be proportional to the number of “+” symbols. The last column resumes the signalling pathways represented by the stated protein mutants and whether the path is enhanced (↑) or interrupted (↓).
develop into differentiated thyroid cancer first, then undifferentiated and eventually to anaplastic thyroid carcinoma (ATC). Early thyroid tumour development correlates with mutation of signalling molecules encoded by five alternative genes: Ras, Ret, trk, gsp, and the TSH receptor; additional mutations in a genome caretaker gene such as p53 ensure genomic instability and would drive evolution towards ATC. Discrete de-differentiation steps difficult to explain are required and also it is rather infrequent that a benign adenoma evolves towards carcinoma; at present, it seems that most thyroid carcinomas are malignant from the onset. The original Ras and Ret mutations seen in FTC and PTC are hardly seen in ATC. These and other observations, particularly from Chernobyl irradiation studies, led to the formulation of an alternative hypothesis based in the existence of cancer stem cells (CSCs) and represented by the horizontal arrows from left to right in figure 1. The CSCs would be derived from embryonic thyroid stem cells, thyroblasts or pro-thyrocytes intermediaries in the pathway of differentiation accumulating mutations that lead to carcinogenesis. The CSCs hypothesis proposes that thyroid cancer develops as a consequence of a block in a differentiation step from any of these intermediaries rather than the process of de-differentiation contemplated by the classical view. The phenotype and incidence of a thyroid cancer type would remember those of the originating CSCs i.e.: the most undifferentiated and aggressive ATC would develop from the earliest and least abundant thyroblasts and would have the lower rate of incidence (2-4). The establishment of ES cell cultures able to differentiate into thyrocytes may clarify these views (5).

**Figure 2.** Known regulatory elements in the promoter of the TSHR: The promoter of TSHR is TATA-less and has multiple transcription start sites (arrows). GA-binding protein (GABP) dimers binding are sensitive to DNA methylation. The cAMP-response element (CRE-like) encompasses a constitutive enhancer that may bind the activators CREB or ATF2 and the repressor ICER. Binding of single strand binding protein (SSBP to the 5’ and 3’ flanking decanucleotide repeats modulates CRE-like site activity. The CRE-like site overlaps with a thyroid hormone response element. Binding of the heterodimer TR/RXR (thyroid hormone receptor and retinoid X receptor) to this site represses transcription. The proximal promoter bears a binding site for the thyroid transcription factor 1, TTF1 and there is at least another binding site at the far 5’ end. The positions in the promoter relative to the transcription start site appear depicted in brackets underneath the sites. Inside of a transcription factor indicates modulation via phosphorylation; Δ indicates modulation via methylation.

**THYROTROPIN BINDING TO ITS RECEPTOR IS THE MAIN STIMULUS FOR THYROCYTE PROLIFERATION**

Thyrotropin (TSH) secreted by the pituitary and bound to its receptor (TSHR) regulates thyroid growth and differentiation at late developmental stages but is not responsible for organogenesis or cell migration according to the phenotypes of the TSHR knockout mice [(6,7), reviewed in (8,9)]. TSH promotes growth of the thyrocyte directly binding to its receptor and also indirectly, stimulating secretion of autocrine growth factors and amyloid precursors (10-12) or the expression of growth factor receptors or of vascular endothelial growth factor, VEGF (13). Additional growth factors, such as insulin/IGF-1 or serum factors (14,15) may be required for TSH induced proliferation of the thyrocyte. Thus, paracrine and autocrine factors secreted by follicular cells, the stromal apparatus and lymphocytes may be implicated in initiation and perpetuation of thyroid hyperplasia. TSH and its receptor are required not only for proliferation in the thyrocyte but also for the expression of differentiation markers such as thyroglobulin, thyroperoxidase or the Na/I symporter (NIS) that is responsible for iodide uptake. These differentiation markers are required for the correct function of thyrocytes that is the synthesis of thyroid hormones. TSH molecules in the membrane are quite stable and signalling in the thyrocyte will be controlled mainly through circulating TSH levels. TSH secretion is inhibited via negative feedback by thyroid hormones; in the absence of thyroid hormones there will be hyper-secretion of TSH and abnormal thyrocyte proliferation.
THE RELEVANCE OF TSHR FOR THE ONSET/EVOLUTION OF THYROID CANCER IS UNCLEAR

The importance of the TSHR signalling for the onset/evolution of thyroid cancer is supported by experiments in which regained expression of functional TSHR in a follicular thyroid cancer cell line (HTC) reduced angiogenesis and size of tumours of xenotransplanted HTC cells (16). Hyperactivated TSHR is commonly found in most adenomas, less common in differentiated carcinomas and the gene is silenced in undifferentiated cancers such as ATC (table 1, see also figure 1). From the point of view of the classical de-differentiation hypotheses, these data from case studies are difficult to interpret; two mutation events on the TSHR gene are highly improbable, but would be required in the evolution from adenoma to ATC: first hyperactivating mutations in adenomas and later silencing in ATC. It would be easier to imagine that the TSHR gene being a susceptible candidate for mutation would mutate differently in different precursor cells undergoing transformation to CSCs. According to the CSCs hypothesis, only one alteration would be required at the TSHR locus to render each transformed phenotype. TSHR implication in the onset of thyroid cancer remains unclear but its functionality is important for thyroid function and treatment of thyroid cancers (see below). Additionally, TSHR may also be relevant in diagnosis. For example, based on the fact that most thyroid cancers still express the TSHR (17), its mRNA has been used as a highly sensitive and specific marker to detect thyroid cancer cells in peripheral blood (18). Differentiated thyroid cancer has better prognosis because the cells express NIS and can be targeted by radioactive $^{131}$I. TSH administration to thyroid cancer patients with functional TSHR ensures NIS expression, uptake of $^{131}$I and the removal of malignant cells left over after ablation of the cancerous gland or nodule. Moreover, differentiated cancers produce thyroid hormones maintaining reduced pituitary TSH secretion. Undifferentiated thyroid carcinomas expressing TSHR but not NIS exist demonstrating that TSHR is required but not sufficient for NIS expression. These cancers are rather difficult to target because radioactive $^{131}$I will not be taken and insufficient thyroid hormone production will result in elevated TSH levels inducing further proliferation even in cells with diminished TSHR numbers.

Hence, signalling from the TSHR may play a role in the onset, evolution, diagnostic and therapies of thyroid cancer.

THE TSHR GENE AND PROTEIN

The TSHR cloned in 1989 (19-22) belongs to the family of the G protein coupled receptors (GPCR) and
contains 7 transmembrane (TM) domains anchored to the basolateral plasma membrane of the thyrocytes and a number of other cells. The TSHR promoter contains functional binding sites for several transcription factors including GABP (23), TTF1 (24), TR/RXR (25), CREB and ICER (26), nevertheless there is little fluctuation in the TSHR mRNA levels and regulation of functional TSHR is mainly exerted at the posttranslational level (27), specially by glycosylation and correct folding at the ER (28).

The mature TSHR is encoded by a single gene with 10 exons (29,30). The protein contains 2 subunits: a large ectodomain also called A or α subunit is encoded by exons 1–8 and binds TSH; a short transmembrane and intracellular domain encoded by exons 9–10 called B or β subunit that will interact with G proteins to initiate signalling. Posttranslational intramolecular cleavage of a 50 aa chain in the ectodomain close to the membrane and reduction of disulphide bridges releases the A and B subunits (29) followed by shedding of the A subunit from the membrane bound receptor (31,32). The presence of the TSHR ectodomain inhibits an otherwise constitutively active β subunit (33) and the interactions between the ectodomain (α), the extracellular loops and transmembrane domain TM6 (in the β subunit) are critical for the maintenance of an inactive state (34). Figure 3 recapitulates the main features in the structure of TSHR. The white dotted line overlapping TM5 and TM6 marks the position of the most frequently found mutations in adenomas. The ectodomain consists mainly of 9 leucine rich repeats (LRR) with interconnecting loops important for receptor structure and activation (35). Precise delineation of the TSH binding pocket of the receptor has been made through deletion-mutation analysis and a panel of antibodies (36,37). The β subunit contains the 7 TM domains joined by extracellular loops (ECL) and intracellular loops (ICL), and interacts selectively with G proteins when the TSHR is activated (34,38). Unstimulated TSHRs form oligomers that return to the monomer state with TSH (39,40). TSHR oligomerisation is an early posttranslational event detectable by FRET (fluorescent resonance energy transfer) in the ER-Golgi (41). After TSH binding, a constitutively oligomeric TSHR dissociates into active monomers, which will be subsequently recruited to the lipid rafts to interact with G proteins (42,43). Systematic mutagenesis of the β subunit has been used to identify critical residues and mechanisms of interactions as illustrated by the following examples. A repulsive separation between TM6 and TM3 in the context of a constitutively active TSHR mutant indicated the opening of the cytoplasmic face of TSHR for G protein coupling (44); mutations in ECL2 and TM6 residues revealed dynamic interactions able to increase or decrease basal TSHR activity (45); deletions and substitutions at the N-terminus of ICL2 served to study TSHR coupling to...
both G_s and G_q and to demonstrate that ICL2–ICL3 interactions are critical for selective G_s activation (34).

Upon TSH binding, cytoplasmic proteins such as β-arrestins bind and desensitize GPCRs uncoupling them from G proteins and promoting their internalization. TSHR binds β-arrestin 2 but does not colocalize with β-arrestins in endosomes (46). β-arrestins effects are pleiotropic and have been shown to act also in signal transduction and in transcription. β-arrestins scaffold some activated GPCRs with the Raf/MAPK/ERK cascade inhibiting nuclear translocation of ERK (47) and some β-arrestins translocate to the nucleus and associate with transcription cofactors such as p300 and CBP at the promoters of genes targeted by the transcription factor CREB (cAMP-Response Element Binding Protein) (48). After desensitizing, TSHR is rapidly internalised by clathrin-coated pits (49,50). Most endocytosed receptors recycle back to the membrane, a vital process to maintain the levels. An adaptor protein, hScrib, is crucial to maintain the correct number of TSHR molecules and to scaffold a correct signalling complex. hScrib interacts with TSHR at the cytoplasmic end of the basolateral membrane of the thyrocyte inhibiting basal TSHR internalization. Upon internalisation, hScrib interaction with the internalised TSHR promotes its recycling. To fulfill this function, hScrib interacts with the C-terminus of the TSHR and recruits several enzymatic activities including GTPase activating proteins and Guanine nucleotide exchange factor (GEF) in a complex required for receptor recycling (51). Finally we must mention here a phenomenon termed “specificity crossover” that consist in the binding and activation of TSHR not only by TSH but also by closely related hormones such as luteinizing (LH) and corionic gonadotropin (hCG) (52,53), a phenomenon that may become important in pathologies that curse with excessive hCG secretion. Indeed variants of hCG with increased TSHR affinity have been described in some patients (54).

3. cAMP-dependent activates PKA by dissociation of its regulatory subunits.

4. Activated PKA phosphorylates target proteins including membrane receptors, signalling molecules and transcription factors changing their activities to promote growth and differentiation. The variety of targets will further amplify and diversify the final outcome of this pathway. Perhaps the most classical target for PKA after translocation of its catalytic subunit to the nucleus is the transcription factor CREB, whose transcriptional activity will be promoted upon phosphorylation by PKA.

Every intermediary in the pathway described may additionally interact with side molecules belonging to other pathways. This will build up a network responsible for refining every response according to a contextual environment. Altered wiring of this network interconnecting TSHR/PKA with other proliferation pathways such as PI3K, BRaf/MAPK or Wnt plays a pivotal role in cancer, and common targets such as CREB or cyclin D1 may need the integrity of the network to be accurately regulated. We will describe next the classical pathway outlining possible important side branches for thyroid cancer, but since it is out of the scope of this review to analyse them in detail, excellent reviews on each pathway can be consulted elsewhere. Figure 4 outlines the main effectors of TSHR and interactions with other signalling pathways.

STEP 1: The TSHR stimulated by TSH interacts with heterotrimeric G proteins

TSH induced dissociation of heterotrimeric G proteins leads to G_s and G_q activation. There are many subtypes of α and βγ subunits, each combination activating a different set of pathways, and there are excellent reviews on the subject [i.e.: (55)].

G_s proteins

Photoaffinity labelling of the TSHR followed by immunoprecipitation suggests that TSHR interacts with all four G_s subtypes (G_s (L), G_s (S), G_s(G11), G_s13, G_s and G_s12) (56), however TSHR signalling in the thyrocyte is mainly mediated by G_s and G_s coupling to increased cAMP production and phosphoinositide turnover respectively. G_s stimulation of AC will increase cAMP, whose major effector is PKA. This path is further analysed below and activating mutations of the TSHR and G_s that increase AC activity have been identified in hyperfunctioning benign follicular adenomas and less commonly in hypofunctioning adenomas and carcinomas of the thyroid. G_s/11 coupling to TSHR in rat FRTL-5 and human thyrocytes

THE CLASSICAL PATHWAY AND THE NETWORK THAT FRAMES TSH ACTION IN THE THYROCYTE

Thyrocyte growth occurs mainly through the TSHR mediated increase in cAMP. cAMP-dependent protein kinase (PKA) activation will follow as described below:

1. TSH stimulated TSHR dissociates the heterotrimeric G protein activating the G_s subunit.

2. G_s-dependent activation of adenyl cyclase (AC) follows, increasing cAMP production.
stimulates phospholipase C (PLC\(\beta\)) (57,58), which catalyses hydrolysis of phosphatidyl inositols in the membrane yielding di-acyl-glycerol (DAG) and inositol tri phosphate (IP3) as second messengers. DAG directly stimulates PKC. IP3 increase cytosolic Ca\(^{2+}\) levels (59), which act through a number of effectors including PKC. PKC stimulation is important in thyroid cancer because it is the major effector of tumor promoters such as phorbol esters, and its activation leads to proliferation and de-differentiation in FRTL-5 and PC CL3 thyrocytes (60,61). TSHR mediated activation of the PLC-Ca\(^{2+}\) cascade has been controversial because it requires very high TSH concentrations in human primary thyrocytes and in FRTL-5 cells (62-64), however, TSHR clearly increases Ca\(^{2+}\) mobilizations at least in certain contexts such as repeated stimulation or simultaneous activation of other GPCRs (65). Increases in PLC-PKC activities have been reported in thyroid carcinomas (66) but it could be due to activation of other receptors because TSHR is poorly expressed in neoplastic tissue (67); moreover, there is a negative feed back from PKC to PLC\(\beta\) in thyroid carcinomas (68), and constitutively active mutants of G\(\alpha_q\) have never been found in thyroid neoplasms (69), although the mutation induces thyroid hyperplasia in mice. Hence, the significance of the TSHR-G\(\alpha_q\)-PLC-PKC in thyroid cancer still remains obscure. Different G proteins compete for binding of the TSHR (70) mainly G\(\alpha_s\) or G\(\alpha_q\) in thyrocytes which activate the PKA or PKC pathways respectively. Functional interference between the cAMP/PKA and PKC pathways has been described in normal thyrocytes (71,72) and in hyperfunctioning thyroid adenoma bearing G\(\alpha_s\) mutants that induce the cAMP cascade and suppress the PLC-Ca\(^{2+}\) signalling (73). Transgenic mice expressing G\(\alpha_s\) mutants that constitutively activate both AC and PLC suggest that these cascades may cooperate in vivo towards development of thyroid follicular malignancies (74).

Finally, TSHR may also couple to G\(\alpha_i1-3\), which will inhibit AC and decrease CAMP levels providing a mechanism to desensitise the TSHR.
**STEP 1: GPCRs and PI3Ks (77)**. In the thyrocyte, GPCRs including phospholipases (75), ACs (76), other GTPases and PI3Ks (77). In the thyrocyte, G<sub>βγ</sub> subunits would allow at least 60 possible combinations, but the composition of the G<sub>βγ</sub> dimers in thyrocytes has not been examined in that detail. More than 20 effectors have been reported for G<sub>βγ</sub> activation including phospholipases (75), ACs (76), other GPCRs and PI3Ks (77). In the thyrocyte, G<sub>βγ</sub> directly activates PLC<sub>β</sub> and PKC, which activates the PKB/Akt pathway. Our lab has shown that TSHR mediated G<sub>βγ</sub> activation directly stimulates PI3K in rat thyrocytes leading to diminished NIS expression (Zaballos, MA et al. 2007 submitted).

In summary, TSHR coupling to G proteins provides the opportunity for activation of the PKA, PKC and PI3K pathways, but mutations in G proteins hardly correlate with thyroid cancers, and hot thyroid nodules with constitutively active TSHR mutants very often bear reduced G<sub>α</sub> protein expression presumably as a mechanism of desensitizing the TSHR (78).

**STEP 2: TSHR-dependent activation of G<sub>βγ</sub> stimulates the AC increasing cAMP levels**

cAMP has cell type specific effects and the outcome on proliferation is largely attributed to cross talk with the Ras-Raf-MAPK-ERK pathway. Besides PKA, a number of cAMP effectors may cross talk with the MAPK pathway in the thyrocyte mainly GTP-exchange factors (GEFs or Epac). Finally, other cAMP effectors in the thyrocyte include cAMP-gated membrane ion channels (79), and some phosphodiesterases (PDEs) such as PDE4. Steady state cAMP levels result from production by AC and degradation by PDEs. cAMP-PKA-dependent PDE4 activation feeds back negatively providing a mechanism to stop the signal (80). Given the enormous variety of cAMP effectors, our understanding of this very complex pathway is far from complete.

**cAMP-dependent PKA activation by binding to its regulatory subunits is analysed in “Step 3” and here we briefly discuss other cAMP effectors. Although PKA activation in thyroid cells is necessary for cAMP mitogenic effects (15), it is not sufficient (81). In fact, cAMP inhibits growth in some human thyroid tumoral cell lines (82,83) perhaps involving negative feed back mechanisms such as over expression of PDE4, as described for autonomous hyperfunctioning thyroid nodules bearing constitutive activation of the cAMP pathway (84). In autonomous hyperplasic thyroid ade-

**nomas with constitutive activation of the cAMP pathway by TSHR and G<sub>α</sub> mutants is not sufficient to generate toxic thyroid adenomas (85). Cooperation with other signalling pathways initiated by insulin/IGF-1, bFGF, EGF or serum factors (14,15) is required by TSH in thyrocytes to display full mitogenic activity. Other cAMP effectors include GEF or Epac, which activate the small GTPases Rap1, Rap2 and Ras, providing another mechanism for diversification and tuning of the signal. The thyrocyte is highly enriched in Epacs (86-88). GTP bound Rap1 may activate Raf-1, B-Raf or C-Raf leading to activation of MAPK/ERK1/2 or p38 MAPK and mitogenesis; Rap1 is over expressed in thyroid follicular cancer (89), and mutations in its effector B-Raf are present in most PTC. Activated Ras signalling may lead to MAPK or to PI3K/PDK1 activation, both pathways being involved in mitogenesis. Ras is required for cAMP dependent mitogenesis in several rat thyroid cell lines such as FRTL-5 and WRT (90,91) and in 60–70% follicular thyroid adenomas, and carcinomas components of the RET/Ras/B-RAF signalling pathway are mutated (92-96). The role of this pathway is further discussed under the epigraph “Networking the TSHR” and has been widely reviewed elsewhere.

**STEP 3: cAMP-dependent activation of PKA**

PKA is composed of 2 catalytic and 2 regulatory subunits that bind CAMP. To date at least 3 different catalytic and 4 regulatory subunits have been found and depending on the combination the corresponding PKA molecules will be targeted to cytosolic substrates (PKA I) or to the membrane of certain organelles (PKA II) via a family of proteins called A kinase anchoring proteins or AKAPs (97). Selective activation of the cytosolic or membrane anchored forms of PKA in the thyrocyte has demonstrated specialised functions. PKA I stimulation increased iodide uptake in FRTL5 cells without affecting gene transcription while selective PKA II activation induced gene transcription and proliferation in FRTL5 cells (98).

Mutations that activate the catalytic subunits or inactivate the regulatory subunits would lead to the constitutive PKA activity found in endocrine tumors but so far no mutants for the catalytic subunits have been correlated to endocrine tumors. Inactivating mutations in the regulatory subunit RI leading to PKA I stimulation has been related to benign endocrine neoplasms, functioning nodules and follicular carcinomas of patients with Carney complex (99). However, selective PKA I activation by cAMP analogs showed anti proliferative activity in BRAF-mutated cells. PKA...
II appears to be more clearly involved: silencing its regulatory subunit RIIβ impairs TSH nuclear effects, and loss of RIIβ expression in three human cancer cell lines suggests an essential role for PKA II in TSHR-mediated proliferation (98).

The transcription factor CREB is the classical nuclear target of PKA, although it is also targeted by other pathways, and PKA also targets other nuclear factors as we will see below.

**STEP 4: PKA dependent activation of the transcription factor CREB**

The ubiquitous transcription factor CREB binds to cAMP response elements and upon activation stimulates transcription at selected promoters (88). Transcription factors from the CREB/CREM family are required for cAMP-dependent proliferation in dog thyroid primary cultures and are tightly regulated by TSH and other factors (26). CREB activity has been shown to be important for TSH dependent thyrocyte proliferation in vitro and in vivo although it is not sufficient to mimic TSH-dependent DNA synthesis. In vitro, the importance of CREB was tested by stable transfection of FRTL-5 cells with either wild type CREB, which did not affect growth, or a dominant negative version dnCREB, which reduced up to 40% TSH-induced growth of the thyrocytes (100). In vivo, transgenic mice with targeted expression of dnCREB to their thyroid glands exhibited severe growth retardation and primary hypothyroidism; dnCREB inhibited the expression of the genes for Pax8, TTF-1, and TTF-2, which are required for the expression of TSHR, thyroglobulin and thyroperoxidase (101). Alterations of CREB family members can be observed in endocrine tumors (102), and levels of total CREB are markedly reduced in thyroid carcinomas (103), but their role in thyroid cancer remains highly controversial. Contradictory results have been reported in hyperfunctioning thyroid adenomas: some laboratories find a reduction of P-CREB (Ser 133) (104) while others do not find differences between nodular and extranodular tissue (103). Perhaps the interpretation of these results is too simplistic having in mind the multiple modifications that would affect CREB activity. It is generally believed that recruitment of the coactivators CREB-binding protein (CBP) and p300 after signal induced phosphorylation of CREB at Ser 133 strongly enhances its transcriptional activity. However, a number of kinases may phosphorylate CREB in Ser 133 including PKA, PKB/Akt, PKC, Rsk1/2. CREB activation can also be promoted by Ser 133 independent mechanisms and not all the signals that induce Ser 133 phosphorylation of CREB enhance its transcriptional activity. Furthermore, CREB is subjected to other phosphorylations, de-phosphorylations (by PP2A and PP1), acetylation by CBP, ubiquitylation and SUMOylation and, depending on its modifications, CREB interacts with other proteins that may perturb its localisation and/or turnover leading to activity changes [reviewed in (105,106)]. Thus CREB acts as a platform targeted by multiple signalling pathways where interference or integration takes place to render a gene expression profile extraordinarily tuned to incoming signals. CREB may use coactivators that are effectors of other signalling pathways (i.e. the Wnt effector β-catenin) and targets a number of genes involved in diverse aspects of proliferation, for example cyclin D1, which is also targeted by the Wnt signalling pathway and others. This provides new opportunities for integration. A complete genome wide analysis of CREB target genes has recently been published (107). Furthermore, other transcription (co)factors involved in proliferation such as β-catenin and others are also activated by PKA.

**TSHR ALTERATIONS RELATED TO THYROID CANCER**

Excesses or defaults in TSHR activity may play a role in thyroid disease and cancer. Both can be achieved by a number of mechanisms including: improper epigenetic marking of the gene, incorrect transcriptional regulation or mutations in critical domains.

**Altered levels of TSHR expression**

Lack or low TSHR expression correlates with aberrant methylation of the promoter in human thyroid carcinomas and in thyroid cancer cell lines (108). The silencing mechanism may also include the binding of the methylation-sensitive GABP transcription factor (23). TSHR function is required for NIS expression and iodide uptake. Low or absent TSHR expression and lack of NIS expression correlates with thyroid carcinomas of the worse prognostic that cannot be eliminated with radioactive iodide (109). Excessive TSHR expression does not correlate with malignant thyroid cancer to our knowledge, although a number of constitutively activating mutations have been described in thyroid adenomas as we describe below.

**Mutations also change the levels of functional TSHR**

Mutations may lead to altered location, turnover or recycling, activation/deactivation, postranslational
modifications or protein-protein interactions, including influences by and on other GPCRs, scaffolding, signaling mediators, desensitisation, etc. TSHR activity is mainly controlled through protein-protein interactions and constitutively active mutants correlate with thyroid adenomas and nodules, while inactivating mutations correlate with diverse forms of hypothyroidism.

**Inactivating mutations**

More than 25 distinct loss-of-function mutations in the TSHR gene have been reported (41,110), including those occurring at the germ line and causing congenital hypothyroidism. So far none of these mutations appear to be related to the onset of thyroid cancer. Inactive TSHR fails to induce thyroid cell proliferation and is unlikely to induce nodule formation. Reduced TSHR expression in thyroid cancers may be secondary to ongoing de-differentiation, may happen in parallel or may cause disappearance of other differentiation markers.

**The TSHR gene is highly susceptible to constitutively activating mutations**

Structural studies discarded TSHR as a candidate oncogene for thyroid tumor (111), however G protein coupling is a critical step and most gain of function mutations are located in exons 9 and 10 corresponding to TM domains (112,113), ICLs or ECLs (114,115). Not surprisingly, these sites are critical for G protein coupling (see figure 3). A list of TSHR mutants may be found at <http://www.uni-leipzig.de/innere/tshr> and we have updated it in table 1. Spontaneous activating mutations of the TSHR gene appear at the onset of autonomous functioning thyroid adenomas (116,117) and more rarely of thyroid carcinomas (118-124). Somatic mutations cause autonomous nodules and germ-line mutations cause congenital hyperthyroidism and hereditary non-autoimmune toxic thyroid hyperplasia. Patients with activating TSHR mutations suffer hyperthyroidism; the disease activity directly correlates with the degree of TSHR activation measured as basal cAMP production (125). Likewise, thyroid nodules and goitre develop earlier in patients carrying TSHR variants with high constitutive receptor (126-130) [reviewed by (131)]. Furthermore, in multinodular goiters different TSHR activating mutations have been found in separate hot nodules of the same gland suggesting a role in true nodule formation (112). Constitutively activating mutations lie also at the root of toxic thyroid adenomas and differentiated thyroid carcinomas (120). Meanwhile, $G_s\alpha$ mutations are very infrequent in hyperthyroidism or toxic adenomas, suggesting that this subunit does not play an important role, a question intensely debated (132,133). Some authors have compared the characteristics and location of the most frequently appearing germ-line and somatic mutations in the TSHR gene. Germ-line mutations are mostly transitions and affect residues [183, 505, 509, and 597] never involved in somatic mutations. Somatic mutations are usually transversions and affect residues 630 and 633 never affected by germ-line mutations. Finally, several residues located in a mutation cluster region [619–639] at TM6 are affected by both somatic and germinal mutations (134).

Thus, the question of whether or not TSHR mutations are involved in the onset of thyroid cancers remains controversial as explained in previous sections. Interpretations are complicated by the fact that biological effects of activating TSHR mutations vary with the ambient iodide supply. In regions of iodine deficiency, higher incidence of toxic adenoma and toxic multi-nodular goitre has been reported, where 50–80% of these toxic adenomas are caused by TSHR mutations (135).

**Posttranslational modifications and protein interactions**

Immunoelectron microscopy studies show that in human thyrocytes most of the TSHR is glycosilated and palmytoylated and is present on the cell surface. Other modifications such as acetylation, methylation, sumoylation, ubiquitination, etc. have not been reported, but interactions with several proteins that may scaffold its signalling or recycle back the endocytosed TSHR are important for its functionality. These TSHR interacting proteins include fibronectin, calreticulin, calnexin, $\beta$-arrestin, Scrib, HSP5, JAK1/2, Stat3, and other GPCRs such as the LHR. Mutations or altered expression in these protein effectors may give a phenotype related to thyroid cancer. For example, over expression of $\beta$-arrestin 2 has been found in thyroid toxic nodules (155). TSHR interacting proteins open new possibilities for networking the signals from the TSHR that will have to be explored. Besides the previously mentioned proteins other related hormones, such as hCG, or antibodies from autoimmune diseases, such as Graves’ disease, may also interact with the TSHR and be involved in thyroid cancers. Anti-TSHR antibodies binding to the TSHR in thyroid nodules might promote growth via direct and indirect mechanisms such as upregulating the expression of insulin receptors (156), which may transduce IGF-II growth effects (157). Anti-TSHR antibodies also stimulate angiogenesis upregulating VEGF and its receptor (flt) in thyroid cells (158). Thus, high levels of anti-TSHR antibodies in Graves’ patients might stimulate thyroid cancer growth and early metastatic spread [an issue that is discussed in (159)].
NETWORKING THE TSH RECEPTOR SIGNALLING IN THYROID CANCER

Cancer arises from accumulation of mutations in important genes or oncogenes. Most known oncogenes are key-signalling molecules important for the integrity of the signalling networks that maintain cell homeostasis. Oncogenes relevant to thyroid carcinogenesis are normally engaged in proliferation and/or survival pathways, the paradigms are RET/Ras/B-Raf, PTEN/Akt and E-cadherin/β-catenin representing the MAPK, PI3K and Wnt pathways respectively. These pathways are integrated in the thyrocyte signalling network among them and with the cAMP/PKA pathway and altering their cross-talk may lead to carcinogenesis.

The MAPK pathway and its cross talk with TSHR/cAMP/PKA

The MAPK pathway in the thyrocyte conveys proliferation signals from tyrosine kinase receptors such as RET. Hyperactivating RET mutations in the kinase domain define MTCs and rearrangements (RET/PTCs) are frequent at early onset of PTCs; RET mutants signal through B-Raf to activate the MAPK pathway in thyroid cells (160), and B-Raf mutations (V600E) are present in more than 40% of PTCs (161,162). The significance of the RET/Ras/B-Raf/ERK pathway in thyroid carcinogenesis has been widely reviewed (163). Crosstalk between the Ras/MAPK/ERK and the cAMP/PKA pathways has long been recognised and cAMP may either suppress or induce the MAPK pathway depending on the cell type (164). RET/PTC2 is a particularly interesting rearrangement cross-linking the MAPK and PKA pathways because the kinase domain of RET is fused to the regulatory subunit of PKA II (165). In FRTL-5 rat thyrocytes, both TSH and cAMP induce ERK (166), and these cells require Ras for TSH-stimulated mitogenesis (90,91); in dog and human thyrocytes, indirect evidence suggest the same because a MEK inhibitor blocks TSH stimulated DNA synthesis (167). cAMP may activate B-Raf and ERK through PKA-dependent or independent mechanisms that need further clarification at the thyrocyte. Thus, in thyroid cells cAMP does not inhibit MAPK signalling but whether it activates it or not remains controversial due to differences among distinct in vitro systems (15). The high sensitivity to B-Raf mutations exhibited by thyrocytes in cancer is intriguing and remarkable and perhaps is exacerbated by the lack of cAMP-dependent mechanisms to suppress B-Raf/ERK activity.

The PI3K/AKT pathway and its crosstalk with TSHR/cAMP/PKA

PI3K/AKT is a pleiotropic kinase downstream of many growth factor receptors involved in cell survival, proliferation and cancer. Indirect evidence of the role of PI3K in thyroid cancer comes from the use of an Akt inhibitor (KP372-1) that suppresses proliferation and induces apoptosis in thyroid cancer cells (168). Activating mutations of Akt or silencing its upstream suppressor PTEN (Phosphatase and TENsin homolog) is frequently associated with thyroid carcinoma (169). PTEN is a dual specificity phosphatase mutated or silenced in the majority of human advanced cancers. Also in thyroid cancers has been found loss, reduction, or inappropriate subcellular compartmentalization of PTEN (170,171). A rearrangement with the histone H4 gene has been found in irradiated thyroid cell lines, H4/PTEN (172). PTEN silencing has been suggested to be involved in the carcinogenesis of highly malignant or late-stage thyroid cancers (170,173), and reintroduction of PTEN in thyroid cancer cell lines causes G1 arrest in the differentiated and apoptosis in the most undifferentiated thyroid cancer cell lines (174). TSHR immunoprecipitates exhibit PI3K activity, which is greater after TSH treatment. Concomitantly, the kinase PDK1 is redistributed from the cytoplasm to the plasma membrane in a PI3K- and PKA-dependent manner after TSH treatment (175). The regulatory subunit of PI3K, p85 phosphorylated at Ser 83, binds the regulatory subunit of PKA, RIβ and mediate TSH-cAMP-PKA growth and survival signals (176). Moreover, the PI3K/Akt pathway has been suggested to be activated in thyroid tumors by RET oncoproteins that associate with RAI (ShcC/N-Shc) and recruit GAB 1 (Graf 2-associated binder 1) (177). Additionally, PI3K is involved in IGF-1 or insulin mediated cooperation with TSH for DNA synthesis in thyrocytes. The interactions between the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways are crucial to regulate growth and may be altered in tumorigenesis.

The Wnt pathway

The Wnt pathway plays a pivotal role in development and in epithelial renewal and components such as β-catenin, APC and E-cadherin are often mutated in thyroid cancer (178,179). β-catenin mutations are more frequent in undifferentiated cancers or ATCs (180,181), and abnormalities of the E-cadherin/catenin complex (methylation of the promoter and silencing or mutations) are associated with the more aggressive behaviour of certain PTCs (182). The Wnt components E-cadherin and β-catenin may crosstalk with the classical TSH/cAMP/CREB pathway to con-
trol thyrocyte proliferation. PKA is known to potenti-
ate Wnt signalling in some cells stabilizing \( \beta \)-catenin and inhibiting GSK3\(\beta \) (183,184). The CREB tran-
scription factor might be targeted by both PKA and Wnt signalling, and recently its role in lithium-stimu-
lated thyrocyte proliferation has been challenged (185). Although these authors conclude that CREB
does not play a role in lithium-induced thyroid prolif-
eration, their experiments do not rule out a possible role of CREB in Wnt-dependent proliferation of thy-
rocytes. Some components of the Wnt pathway (GSK3\(\beta \)) are also targeted by PI3K. Cyclin D1 is a
transcriptional target for both CREB and \( \beta \)-catenin and is over expressed in thyroid papillary microcarci-
noma with aberrant \( \beta \)-catenin (186).

In summary, mutations of individual compo-
nents may cause fundamental functional changes well
beyond the pathway they function in, due to the
crosstalk between signalling pathways. One of the
molecules most mutated in cancer in general and in
ATC also is p53, another common target for many sig-
nalling pathways including PI3K, cAMP, and ERK.
p53 is inactivated in 50% of human cancers and 14% of
malignant thyroid tumors; p53 mutations appear “late” in thyroid carcinogenesis and are associated
with loss of differentiation and transformation to the
anaplastic phenotype (132). p53 is a transcription fac-
tor and plays multiple regulatory functions in the cell
cycle, DNA repair, and apoptosis. Reintroduction of
wild type p53 in thyroid tumoral cell lines arrests
growth and/or induces apoptosis (21,187). p53 pro-
tein levels may be increased by cAMP, ERK, and also
through the activation of PTEN, and recently a differ-
tential proteomic approach has identified several tar-
geted proteins for mutant p53 associated with thyroid
cell transformation (188). The TSHR and p53 con-
nection in thyrocytes still has to be clarified but it is
remarkable that stable expression of a p53 mutant
which does not bind DNA (V143A), induces loss of
transcriptional activity for the growth and causes only loss of TSH dependency for growth (188).

**FUTURE PERSPECTIVES**

Undifferentiated thyroid cancers are among the most
rapid life-threatening and are characterised by abnormal
CpG islands methylation patterns in critical promoters.
Silencing of TSHR, PTEN and p53 appears to be relat-
ed to the most aggressive behaviour of thyroid cancer,
and reintroduction of each of these genes in human thy-
roid cancer cell lines either restores differentiation or
arrest cell cycle or causes apoptosis. Hypomethylation of
heterochromatin has been correlated with tumour pro-
gression in thyroid cancer specimens (189), and hyper-
methylation of tumor suppressor promoters appears in
undifferentiated thyroid cancer causing failure in clinical
radioiodine treatment (171,173). Thus, aberrant DNA
methylation patterns are some of the epigenetic marking
processes more likely involved in the onset of thyroid
cancer. Demethylating agents or inhibitors of the DNA
methylase may be promising hopes in the treatment of
the worse thyroid cancers, but their clinical value remains
to be investigated and they have to be specifically target-
ed. In general, the development of molecular-based
therapies for thyroid carcinoma patients resistant to stan-
dard radioiodine treatment such as histone deacetylase
inhibitors combined with retinoids or the use of specific
targeted RNAis for invasion/metastasis molecules repre-
sent a critical issue and an exciting field in new drug
development in thyroid cancer.

Large chromatin alterations related to thyroid
cancer, such as the chromosomal rearrangements:
RET/PTCs or Pax8/PPAR\(\gamma \) chimeras (190), coincide
in their activation of the Ras/Raf/MEK/ERK path-
way, which is also induced by TSHR signalling in the
thyrocyte. Chromatin alterations related to cancer,
especially epigenetic modifications, need to be further
explored, especially lost of imprinting (LOI) and lost
of heterozigosity (LOH) studies will reveal new clues
to the onset of cancer.

Finally, an exciting aspect in thyroid cancer
research is the definition and biological characterization
of the precursor cells that give rise to thyroid carcinomas.
Mouse embryonic stem cells might now be differentiat-
ed into thyroid follicular cells in vitro (5), and this system
will surely help to identify key events in thyroid carcino-
genesis and understanding the role of TSHR.

**ACKNOWLEDGEMENTS**

We are grateful to grants URJC-CM-2006-BIO-0522
(to CG-J) and BFU 2004-03 169, and FIS PI
041216, PI 042374, RD06 0020 0060 (to PS) for
supporting our work.

**REFERENCES**

1. Davies L, Welch GH. Increasing incidence of thyroid cancer in
   the United States, 1973-2002. **JAMA 2006**;295:2164-7.
2. Takano T. Fetal cell carcinogenesis of the thyroid: a hypothesis for better understanding of gene expression profile and genomic alternation in thyroid carcinoma. *Endocr J* 2004;51:509-15.

3. Takano T. Fetal cell carcinogenesis of the thyroid: Theory and practice. *Cancer Biol* 2007;17(3):233-40.

4. Takano T, Amino N. Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma. *Cancer Biol* 2005;15:432-8.

5. Arufe MC, Lu M, Kubo A, Keller G, Davies TF, Lin RY. Direct differentiation of mouse embryonic stem cells into thyroid follicular cells. *Endocrinology* 2006;147:3007-15.

6. Marians RC, Ng L, Blair HC, Unger P, Graves PN, Davies TF. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin-receptor-null mice. *Proc Natl Acad Sci U S A* 2002;99:15462-7.

7. Brown SR. Minireview: developmental regulation of thyrotropin receptor gene expression in the fetal and newborn thyroid. *Endocrinology* 2004;145:4058-61.

8. Felice DM, Postiglione MP, Lauro DR. Minireview: thyrotropin receptor signaling in development and differentiation of the thyroid gland. *Proc Natl Acad Sci U S A* 2002;99:15465-7.

9. Brown SR. Minireview: developmental regulation of thyrotropin receptor gene expression in the fetal and newborn thyroid. *Endocrinology* 2004;145:4058-61.

10. Takahashi S, Conti M, Wyk VJ. Thyrotropin potentiation of insulin-like growth factor-I dependent deoxribonucleic acid synthesis in FRTL-5 cells: mediation by an autocrine amplification factor(s). *Endocrinology* 1990;126:736-45.

11. Beck's GP, Logan A, Phillips ID, Wang JF, Smith C, DeSouza D, et al. Increase of basic fibroblast growth factor (FGF) and FGF receptor messenger RNA during rat thyroid hyperplasia: temporal changes and cellular distribution. *J Endocrinol* 1994;142:325-38.

12. Pietrzik CU, Hoffmann J, Stober K, Chen CY, Bauer C, Otero DA, et al. From differentiation to proliferation: the secretory amyloid protein precursor as a local mediator of growth in thyroid epithelial cells. *Proc Natl Acad Sci U S A* 1995;92:1770-5.

13. Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, et al. Thyrotrpin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. *J Clin Endocrinol Metab* 2004;89:6139-45.

14. Medina DL, Suzuki K, Pietrarelli M, Okajima F, Kohn LD, Santisteban P. Role of insulin and serum on thyrotropin regulation of thyroid transcription factor-1 and pax-8 genes expression in FRTL-5 thyroid cells. *Thyroid* 2000;10:295-303.

15. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Hassane I, et al. Cloning, sequencing and expression of the cDNA for the human thyrotropin receptor-thyroglobulin and thyroxin peroxidase in neoplastic human thyroid tissues. *Biochem Biophys Res Commun* 1991;174:1148-53.

16. Chia SY, Milas M, Reddy SK, Siperstein A, Skugor M, Brainard J, et al. TSH receptor mRNA measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. *J Clin Endocrinol Metab* 2007;92(2):468-75.

17. Pieris M, Libert F, Maenhaut C, Lefort A, Gerard C, Perret J, et al. Molecular cloning of the thyrotropin receptor. *Science* 1989;246:1820-2.

18. Libert F, Lefort A, Gerard C, Parmentier M, Perret J, Luditge M, et al. Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. *Biochem Biophys Res Commun* 1989;165:1256-60.

19. Nagayama Y, Kaufman DK, Seto P, Rapoport B. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. *Biochem Biophys Res Commun* 1989;165:1188-90.

20. Misrahi M, Loosfelt H, Atger M, Sar S, Guiochon-Mantel A, Milgrom E. Cloning, sequencing and expression of human TSH receptor. *Biochem Biophys Res Commun* 1990;166:394-403.

21. Yokomori N, Tawata M, Saito T, Shimura H, Onaya T. Regulation of the rat thyrotropin receptor gene by the methylation-sensitive transcription factor GA-binding protein. *Mol Endocrinol* 1998;12:1241-9.

22. One K, Ikuyama S, Takayanagi R, Kohn LD, Nawata H. Interferon-gamma suppresses thyrotropin receptor promoter activity by reducing thyroid transcription factor-1 (TTF-1) binding to its recognition site. *Mol Endocrinol* 1996;10:826-36.

23. Chen TS, Lin DJ, Lin HK. Characterization of a thyroid hormone-mediated short-loop feedback control of TSH receptor gene in an anaplastic human thyroid cancer cell line. *J Endocrinol* 2002;175:459-65.

24. Uyttersprot N, Costagliola S, Dumont EJ, Miot F. Requirement for cAMP-response element (CRE) binding protein/CRE modulator transcription factors in thyrotropin-induced proliferation of dog thyroid cells in primary culture. *Eur J Biochem* 1999;259:370-8.

25. Seetharamaiah SG, Dallas SJ, Prabhakar SB. Glycosylated ectodomain of the human thyrotropin receptor induces antibodies capable of reacting with multiple blocking antibody epitopes. *Autoimmunity* 1999;29:21-31.

26. Siffroi PJ, Bourhis LC, Daudone PJ. Collecting human spermatozoa onto filters for FISH: Application to the study of extreme oligozaosperma. *Acta Cytol* 2002;46:1123-8.

27. Loosfelt H, Pichon C, Jolivet A, Misrahi M, Caillou B, Jamous M, et al. Two-subunit structure of the human thyrotropin receptor. *Endocrinology* 2000;145:4058-61.

28. Misrahi M, Ghinea N, Sar S, Saunier B, Jolivet A, Loosfelt H, et al. Processing of the precursors of the human thyroid-stimulating hormone receptor in various eukaryotic cells (human thyrocytes, transfected L cells and baculovirus-infected insect cells). *Eur J Biochem* 1994;222:711-9.

29. Couet J, Sar S, Jolivet A, Hai MT, Milgrom E, Misrahi M. Shedding of human thyrotropin receptor ectodomain. *Involvement of a matrix metalloprotease.* *J Biol Chem* 1999;274:4545-52.

30. Tanaka K, Chazenbalk GD, McLachlan SM, Rapoport B. Subunit structure of thyrotropin receptors expressed on the cell surface. *J Biol Chem* 2000;275:23397-94.

31. Zhang M, Tong KP, Fremont V, Chen J, Narayan P, Puett D, et al. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. *Endocrinology* 2000;141:3514-7.

32. Neumann S, Krause G, Claus M, Paschke R. Structural determinants for g protein activation and selectivity in the second intracellular loop of the thyrotropin receptor. *Endocrinology* 2005;146:477-85.

33. Costagliola S, Kho D, Vassart G. Production of bioactive amino-terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor. *FEBS Lett* 1998;436:427-33.

34. Jeffrey S, Depraetere H, Sanders J, Oda Y, Evans M, Kiddie A, et al. Characterization of the thyrotropin binding pocket. *Thyroid* 2002;12:1051-61.

35. Nunez Miguel R, Sanders J, Jeffrey S, Depraetere H, Evans M, Richards T, et al. Analysis of the thyrotropin receptor-thyrotropin interaction by comparative modeling. *Thyroid* 2004;14:991-1011.
38. Vlaeminck-Guillerm V, Ho SC, Rodien P, Vassart G, Costagliola S. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol Endocrinol 2002;16:736-46.

39. Graves PN, Vlase H, Bobovnikova Y, Davies TF. Multimeric complex formation by the thyrotropin receptor in solubilized thyroid membranes. Endocrinology 1996;137:3915-20.

40. Latif R, Graves P, Davies FT. Ligand-dependent inhibition of oligomerization by mutants linked to dominant TSH resistance. Hum Mol Genet 2005;14:2991-3002.

41. Moffett S, Brown AD, Linder EM. Lipid-dependent targeting of G proteins into rafts. J Biol Chem 2000;275:2191-8.

42. Davies T, Marians R, Latif R. The TSH receptor gets revealed. J Clin Invest 2002;110:161-4.

43. Ringkananont U, Van Durme J, Montelanni L, Ugrasbus F, Yu YM, Weis RE, et al. Repulsive separation of the cytoplasmic ends of transmembrane helices 3 and 6 is linked to receptor activation in a novel thyrotropin receptor mutant (M626I). Mol Endocrinol 2006;20:893-903.

44. Kleinau G, Brehm M, Wiedemann U, Labudde D, Leser U, Krause G. Conformations of molecular mechanisms of G protein receptor homologues using a new sequence-structure-function analysis resource. Mol Endocrinol 2007;21:574-80.

45. Frenzel R, Voigt C, Paschke R. The human thyrotropin receptor is predominantly internalized by beta-arrestin 2. Endocrinology 2006;147:3114-22.

46. Caunt CJ, Finch AR, Sedgley KR, Oakley L, Luttrell LM, McArdle CA. Arrestin-mediated ERK activation by gonadotropin-releasing hormone receptors: receptor-specific activation mechanisms and compartmentalization. J Biol Chem 2006;281:2701-10.

47. Ma L, Pei G. beta-arrestin signaling and regulation of transcription. J Cell Sci 2007;120:213-8.

48. Baratti-Elbaz C, Ghinea N, Lahuna O, Loosfelt H, Pichon C, et al. Thyrotropin receptor trafficking relies on the hScrib negative G subunit that prevents thyroid-stimulating hormone action. J Biol Chem 2000;275:21305-13.

49. Milgrom E. Internalization and recycling pathways of the thyrotropin receptor. Mol Endocrinol 1999;13:1751-65.

50. Singh PS, McDonald D, Hope JT, Prabhakar BS. Upon thyrotropin binding the thyrotropin receptor is internalized and localized to endosome. Endocrinology 2004;145:1003-10.

51. Lahuna O, Quellet M, Achar C, Nola S, Meduri G, Navarro C, et al. Thyrotropin receptor trafficking relies on the NScrib beta-arrestin-2 pathway. J Biol Chem 2005;280:1364-74.

52. Graves NP, Davies FT. Absence of lutropin (LH) receptor mRNA in the rat thyroid: further evidence for specificity across the thyrotropin-stimulating hormone receptor level. Mol Cell Endocrinol 1991;79:21-8.

53. Urizar E, Montelanni L, Loy T, Bonomi M, Swillens S, Gales C, et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. Embo J 2005;24:1954-64.

54. Kriemel Z, Lahat N, Sadeh O, Blithe DL, Nisula BC. Desialylated and deglycosylated human choriionic gonadotropin are superagonists of native human chorionic gonadotropin in human thyroid follicles. Thyroid 1997;7:783-8.

55. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, et al. Insights into G protein structure, function, and regulation. Endocr Rev 2003;24:765-81.

56. Laugwitz KL, Allgeier A, Offermanns S, Spicher K, Van Sande J, Dumont JE, et al. The human thyrotropin receptor: a heptahedral receptor capable of stimulating members of all four G protein subunits. Proc Natl Acad Sci U S A 1996;93:1136-20.

57. Jhon DY, Lee HH, Park D, Lee CW, Lee KH, Yoo OJ, et al. Cloning, sequencing, purification, and Gq-dependent activation of phospholipase C-beta. J Biol Chem 1993;268:8564-61.

58. Allgeier A, Offermanns S, Van Sande J, Spicher K, Schultz G, Dumont JE. The human thyrotropin receptor activates G proteins Gs and Gq/11. J Biol Chem 1994;269:13733-5.

59. Newton AC. Agonist activation of protein kinase C. Curr Opin Cell Biol 1997;9:161-7.

60. Gallo A, Benuisiglio E, Bonapace IM, Ficellioci A, Cassano S, Garbi C, et al. v-ras and protein kinase C dedifferentiate thyroid cells by down-regulating nuclear cAMP-dependent protein kinase A. Genes Dev 1992;6:1621-30.

61. Portella G, Vitaligliano D, Li Z, Sferratore F, Santoro M, Vecchio G, et al. TPA induces a block of differentiation and increases the susceptibility to neoplastic transformation of a rat thyroid epithelial cell line. Oncol Res 1998;10:441-7.

62. Wang JF, Hill DJ, Beckes GP. Role of 3', 5' cyclic adenosine monophosphate and protein kinase C in the regulation of insulin-like growth factor-binding protein secretion by thyroid-stimulating hormone in isolated ovine thyroid cells. J Endocrinol 1994;141:231-42.

63. D'Arcangelo D, Silletta MG, Di Francesca AL, Bonfitto N, Di Cerbo A, Falasca M, et al. Physiological concentrations of thyrotropin increase cytosolic calcium levels in primary cultures of human thyroid cells. Mol Cell Endocrinol 1996;110:1136-43.

64. Yanagita Y, Okajima F, Sho K, Nagamachi Y, Kondo Y. An adenosine derivative cooperates with TSH and Graves' IgG to induce Ca2+ mobilization in single human thyroid cells. Mol Cell Endocrinol 1995;80:113-46.

65. Metacalf RA, Findlay C, Robertson WR, Weetman AP, Mac Neil S. Differential effect of thyrotropin-stimulating hormone (TSH) on intracellular free calcium and cAMP in cells transfected with the human TSH receptor. J Endocrinol 1998;157:415-24.

66. Kobayashi K, Shaver JK, Liang W, Siperstein AE, Duh QY, Clark GH. Increased phosphorylase C activity in neoplastic thyroid membrane. Thyroid 1993;25:29-9.

67. Brabant G, Maenhaut C, Kohrle J, Scheumann G, Drale H, Hoang-Vu C, et al. Human thyrotropin receptor gene expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991;82:R7-12.

68. Broecker M, Mayr GW, Derwah MI. Suppression of thyrotropin receptor-G protein-phospholipase C coupling by activation of protein kinase C in thyroid carcinoma cells. Endocrinology 1997;138:3787-96.

69. Ringel MD, Saji M, Schwindinger WF, Segev D, Zeiger MA, Levine MA. Absence of activating mutations of the genes encoding the a subunits of G11 and Gq in thyroid neoplasia. J Clin Endocrinol Metab 1998;83:584-9.

70. Cletator JH, Ravellen R, Kurtz DT, Hildebrandt JD. A dominant negative Gs mutant that prevents thyroid-stimulating hormone receptor activation of Ca2+ production and inositol 1,4,5-trisphosphate turnover: competition by different G proteins for activation by a common receptor. J Biol Chem 2001;276:39691-7.

71. Sho KM, Okajima F, Abdul Majid M, Kondo Y. Reciprocal modulation of thyrotropin actions by PT1-purinergic agonists in FRTL-5 thyroid cells. Inhibition of cAMP pathway and stimulation of phospholipase C-Ca2+ pathway. J Biol Chem 2001;276:121804-9.

72. Laglia G, Zeiger MA, Leipricht A, Caturegli P, Levine MA. Absence of activating mutations of the genes encoding the a subunits of G11 and Gq in thyroid neoplasia. J Biol Chem 1993;41:137-42.

73. Ledent C, Befort DF, Cotticchia S, Lefkowitz R, Dumont J, Vassart G, et al. Costimulation of adenylyl cyclase and phospholipase C by a mutant a1b-adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells. Endocrinology 1997;138:369-78.

74. Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isoforms. J Biol Chem 1997;272:15045-8.

75. Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 1996;36:461-80.
77. Vanhaesebroeck B, Leeners SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. *Trends Biochem Sci* 1997;22:267-72.

78. Holzapfel HP, Bergner B, Wonerow P, Paschke R. Expression of Gs proteins and TSH receptor signalling in hyperfunctioning thyroid nodules with TSH receptor mutations. *Eur J Endocrinol* 2002;147:109-16.

79. Kaupp UB, Seifert R. Cyclic nucleotide-gated ion channels. *Physiol Rev* 2002;82:679-824.

80. MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seams R, McSorley T, et al. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). *Br J Pharmacol* 2002;136:421-33.

81. Dremier S, Vandeput F, Zwartkruis FJ, Bos JL, Dumont JE, Maenhaut C. Activation of the small G protein Rap1 in dog thyroid cells by both cAMP-dependent and -independent pathways. *Biochem Biophys Res Commun* 2000;267:7-11.

82. Derwah M, Kaeemmell M, Goretzki P, Schatz H, Broecker M. Expression of the human TSH receptor in a human thyroid carcinoma cell line that lacks an endogenous TSH receptor: growth inhibition by cAMP. *Biochem Biophys Res Commun* 1993;191:1131-8.

83. Ohta K, Hig XP, Berg L, Hershman JM. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenyly cyclase through the β-adrenergic receptor. *J Clin Endocrinol Metab* 1978;52:2633-8.

84. Persani L, Lania A, Alberti L, Romoli R, Mantovani G, Feltiti S, et al. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. *J Clin Endocrinol Metab* 2000;85:2872-3.

85. Derwah M, Manole D, Sombre A, Broecker M. Pathogenesis of toxic thyroid adenomas and nodules: relevance of activating mutations in the TSH-receptor and Gsα gene, the role of iodine deficiency and secondary and TSH-independ-ent molecular mechanisms. *Exp Clin Endocrinol Diabetes* 1998;106(suppl 4):S6-9.

86. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matuda M, et al. A family of cAMP-binding proteins that directly activate Rap1. *Science* 1998;282:2275-9.

87. Kawasaki H, Springett GM, Toki S, Canales JJ, Harlan P, Blu-menstiel JP, et al. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. *Proc Natl Acad Sci U S A* 1998;95:13278-83.

88. Richards JS. New signaling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells. *Cell Mol Biol (Noisy-le-grand)* 1995;41:105-11.

89. Puskas LG, Juhász F, Zarva A, Hacker L Jr, Farid NR. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. *Cell Mol Biol (Noisy-le-grand)* 2005;51:127-36.

90. Miller MJ, Rioux L, Prendergast GV, Cannon S, White MA, Ciullo I, Diez-Roux G, Di Domenico M, Migliaccio A, Avvedimento E. cAMP signalling selectively influences Ras effectors pathways. *Mol Cell Biol* 1998;18:3718-26.

91. Ciullo I, Diez-Roux G, Domenico M, Migliaccio A, Avvedimento E. cAMP signalling selectively influences Ras effectors pathways. *Oncogene* 2001;20:1186-92.

92. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Take-bayashi Y, et al. BRAF mutations in papillary carcinomas of the thyroid. *Oncogene* 2003;22:6455-7.

93. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Res* 2003;63:1454-7.

94. Soares P, Marques V, Sbíroho-Simões M. Molecular pathology of papillary, follicular and Hurthle cell carcinomas of the thyroid. *Arkhe Patol* 2003;65:45-7.

95. Xu X, Quiros RM,Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. *Cancer Res* 2003;63:4561-7.

96. Williams SF, Smallridge RC. Targeting the ERK pathway: novel therapeutics for thyroid cancer. *Curr Drug Targets Immune Endocr Metab Disord* 2004;4:199-220.

97. Wong W, Scott JD. AKAP signalling complexes: focal points in space and time. *Nat Rev Mol Cell Biol* 2004;5:959-70.

98. Calebro d, De Filippis T, Lucchi S, Martinez F, Porazzi P, Triv-ellato R, et al. Selective modulation of protein kinase A and II reveals distinct roles in thyroid cell gene expression and growth. *Mol Endocrinol* 2006;20:3196-211.

99. Kirchner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, et al. Mutations of the gene encoding the protein kinase A type-α regulatory subunit in patients with the Carney complex. *Nat Genet* 2000;26:89-92.

100. Woloshin P, Walton KM, Rehfuss GP, Goodman RH, Cone RD. ‘3′,-cyclic adenosine monophosphate-regulated enhancer binding (CREB) activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line. *Mol Endocrinol* 1992;6:1725-33.

101. Nguyen LQ, Kopp P, Martinson F, Stanfield K, Roth SJ, Jame-son JL. A dominant negative CREB (cAMP response element-containing protein) isoform inhibits thyrocyte growth, thyroid-specific gene expression, differentiation, and function. *Mol Endocrinol* 2000;14:1448-61.

102. Rosenberg D, Broussin L, Juillan E, Perlemane K, Bertagna X, Bertherat J. Role of the β2-AR-regulated transcription factor CREB in development and tumorigenesis of endocrine tis-sues. *Ann N Y Acad Sci* 2002;986:65-74.

103. Luciani P, Buci L, Conforti B, Tonacherra M, Agretti P, Elsei R, et al. Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. *Eur J Endocrinol* 2003;148:579-86.

104. Brunetti A, Chiefari E, Feltiti S, Russo D. The 3′,5′-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. *Endocrinology* 2000;141:722-30.

105. Johanssenes M, Delhjardt MP, Moens U. What turns CREB on? Cell Signal 2004;16:1211-27.

106. Johanssenes M, Moens U. Multi-site phosphorylation of the cAMP response element-binding protein (CREB) by a diversi-ty of protein kinases. *Front Biosci* 2007;12:1814-32.

107. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. *Proc Natl Acad Sci U S A* 2005;102:4459-64.

108. Xing M, Usadell H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, et al. Methylation of the thyroid-stimulating hormone recep-tor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. *Cancer Res* 2003;63:2316-21.

109. Mirebeau-Prunier D, Guyetant S, Rodien P, Franc B, Baris O, Rohmer V, et al. Decreased expression of thyrotropin recep-tor gene suggests a high-risk subgroup for oncogenic acrocy- ma. *Eur J Endocrinol* 2004;150:269-76.

110. Fricke-Otto S, Pfann N, Muehlenberg R, Pohienz J, Milden-congenital primary hypothyroidism in a Turkish family caused by a homozygous missense thyrotropin receptor (TSHR) gene mutation (A593 V). *Exp Clin Diabetes* *Mol Endocrinol* 2005;113:582-5.

111. Matsuoka K, Friedman E, Gejman PV, Fagin JA. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. *J Clin Endocrinol Metab* 1993;76:1446-51.

112. Krohn K, Paschke R. Somatic mutations in thyroid nodular disease. *Mol Metab* 2002;7:202-8.

113. Rodien P, Ho SC, Vlaeminck V, Vassart G, Costagliola S. Acti-vating mutations of TSH receptor. *Ann Endocrinol (Paris)* 2003;64:12-6.

114. Duprez L, Parma J, Van Sande J, Allgieer A, Leclere J, Schwartz C, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autonomous dominant hyperthyroidism. *Nat Genet* 1994;7:396-401.
115. Russo D, Arturi F, Chiefari E, Filetti S, Schwartz C, Visinewski P, et al. Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 1996;81:547-54.

116. Russo D, Arturi F, Chiesa E, Filetti S. Molecular insights into TSH receptor abnormality and thyroid disease. J Endocrinol Invest 1997;20:36-47.

117. Arturi F, Cappuccini C, Chiefari E, Filetti S, Russo D. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. Exp Clin Endocrinol Diabetes 1998;106:234-6.

118. Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVillard JA, et al. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995;80:1347-51.

119. Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, et al. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. J Clin Endocrinol Metab 1997;82:735-8.

120. Russo D, Wong MG Costante G, Chiefari E, Tumino S, Arturi F, et al. A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 1999;9:13-7.

121. Spambagl D, Sharifi N, Elisi R, Gross JL, Medeiros-Neto G, Fagin JA. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab 1996;81:3898-901.

122. Esapa C, Foster S, Johnson S, Jameson JL, Kendall-Taylor P, Harris PE. G protein and thyrotropin receptor mutations in thyroid neoplasia. J Clin Endocrinol Metab 1997;82:493-8.

123. Cetani F, Tonacchera M, Pinchera A, Barsacchi R, Basolo F, Miccoli P, et al. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinoma. J Endocrinol Invest 1998;21:273-8.

124. Camacho P, Gordon D, Chiefari E, Yong S, DeJong S, Pitale S, et al. A Phe 488 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism. Thyroid 2000;10:1099-12.

125. Corvilaiv B, Van Sande J, Dumont JE, Vassart G. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin Endocrinol (Oxf) 2001;55:143-58.

126. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, et al. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995;332:150-4.

127. de Roux N, Polak M, Coutej D, Leger J, Czernichow P, Milgrom T, et al. Neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab 1996;81:2023-6.

128. Fuhrer D, Holzapfel HP, Wonerow P, Scherbaum WA, Paschke R. Somatic mutations in the thyrotropin receptor gene and not in the Gs protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997;82:3885-91.

129. Holzapfel HP, Fuhrer D, Wonerow P, Weinland G, Scherbaum WA, Paschke R. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab 1997;82:4229-35.

130. Tonacchera M, Agretti P, Chiovato L, Rosellini L, Ceeccarini G, Perri A, et al. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiters. J Clin Endocrinol Metab 2000;85:2270-4.

131. Karges W. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5. J Endocrinol 2005;186:377-85.

132. Learoyd DJ, Mestha M, Zedenius J, Robinson BG. Molecular genetics of thyroid tumors and surgical decision-making. World J Surg 2000;24:923-33.

133. Trulzsch B, Kohn K, Wonerow P, Chey S, Holzapfel HP, Ackermann F, et al. Detection of thyroid-stimulating hormone receptor and Gs mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 2001;79:684-91.

134. Farid NR, Kascur V, Balazs C. The human thyrotopin receptor is highly mutable: a review of gain-of-function mutations. Eur J Endocrinol 2000;143:25-30.

135. Al-Khafaji F, Wiltshire M, Fuhrer D, Mazzioletti G, Lewis MD, Smith PJ, et al. Biological activity of activating thyrotropin receptor mutants: modulation by iodide. J Mol Endocrinol 2005;34:209-20.

136. R. SC, Van Sande J, Lefort A, Vassart G, Costagliola S. Effects of mutations involving the highly conserved S281HC motif in the extracellular domain of the thyrotrophin (TSH) receptor on TSH binding and constitutive activity. Endocrinology 2001;142:2760-7.

137. Biebergmann H, Schoneberg T, Hess C, Germak J, Gudermann T, Gruters A. The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism. J Clin Endocrinol Metab 2001;86:4229-33.

138. Elgadi A, Arvidsson CG, Janson A, Marcus C, Costagliola S, Norgren S. Autosomal-dominant non-autoimmune hyperthyroidism presenting with neuromuscular symptoms. Acta Paediatr 2005;94:1145-8.

139. Arturi F, Chiefari E, Tumino S, Russo D, Squatrito S, Chazenbalk GD, et al. Does a Leu 512 Arg thyrotropin receptor mutation cause an autonomously functioning papillary carcinoma? J Endocrinol Invest 2002;25:696-701.

140. Parma J, Van Sande J, Swillens S, Tonacchera M, Dumont J, Vassart G. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctional thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphates-Ca2+ cascades. Mol Endocrinol 1995;9:725-33.

141. Kosugi S, Hail N, Okamoto H, Sugawa H, Mori T. A novel activating mutation in the thyrotropin receptor gene in an autonomously functioning thyroid adenoma developed by a Japanese patient. Eur J Endocrinol 2000;143:471-7.

142. Vaidya B, Campbell V, Tripp JH, Spyer G, Hattersley AT, Ellard S. Premature birth and low birth weight associated with nonautoimmune hyperthyroidism due to an activating thyrotropin receptor gene mutation. Clin Endocrinol (Oxf) 2004;60:711-8.

143. Gozu H, Avasar M, Bircan R, Sahin S, Ahsikanuli R, Gullugolu B, et al. Does a Leu 512 Arg thyrotropin receptor mutation cause an autonomously functioning papillary carcinoma? Thyroid 2004;14:975-80.

144. Sykiotis GP, Gourou S, Papachatzopoulos A, Markou KB, Kyriazopoulos V, Papavassiliou AG, et al. A somatic mutation in the thyrotropin receptor gene in a patient with an autonomous nodule within a multinodular goiter. Hormones (Athens) 2002;1:42-6.

145. Nishihara F, Fukuta S, Hishinuma A, Ohye H, Tsuchida K, et al. Sporadic congenital hyperthyroidism due to a germline mutation in the thyrotropin (TSH) receptor gene. J Clin Endocrinol Metab 2001;86:2873-81.

146. Arq Bras Endocrinol Metab 2007;51/5
149. Niepomniszcze H, Suarez H, Pitaio F, Pignatta A, Danilowicz K, Manavela M, et al. Follicular carcinoma presenting as an autonomously functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. *Thyroid* 2008;18:497-503.

150. Ludgate M, Gire V, Crisp M, Ajran R, Weetman A, Ivan M, et al. Contrasting effects of activating mutations of Gus and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells. *Oncogene* 1999;18:4798-807.

151. Gozu H, Avasar M, Bircan R, Claus M, Sahin S, Sezgin O, et al. Two novel mutations in the sixth transmembrane segment of the thyrotropin receptor gene causing hyperfunctioning thyroid nodules. *Thyroid* 2008;18:399-97.

152. Gozu H, Avasar M, Bircan R, Sahin S, Deynali O, Cirakoglu B, et al. Mutations in the thyrotropin receptor signal transduction pathway in the hyperfunctioning thyroid nodule fractions from multinodular goiter: a study in the Turkish population. *Endocr J* 2005;52:577-85.

153. Nwosu BU, Gouriotis L, Gershengorn MC, Neumann S. A novel activating mutation in transmembrane helix 6 of the thyrotropin receptor as cause of hereditary nonautoimmune hyperthyroidism. *Thyroid* 2006;16:505-12.

154. Fuhrer D, Tannapfel A, Sabri O, Lamesch P, Paschke R. Two somatic TSH receptor mutations in a patient with toxic metastasizing follicular thyroid carcinoma and non-functioning lung metastases. *Endocr Relat Cancer* 2010;10:591-600.

155. Voigt C, Holzapfel H, Paschke R. Expression of β-arrestins in toxic and cold thyroid nodules. *FEBS Lett* 2000;486:208-12.

156. Van Keymeulen A, Roger PP, Dumont JE, Denuer S. TSH and cAMP do not signal mitogenesis through Ras activation. *Biochem Biophys Res Commun* 2000;273:154-8.

157. Frasca F, Pandini G, Scalca L, Mineo R, Costantino C, et al. Activating mutation of the Ki-RAS (G12C) genes in thyrotropin receptor-positive pools. *Cell Signal* 2003;15:529-37.

158. K Y, Yamazaki K, Shiuzme K, Kajani Y, Obara T, Ohsumi K, et al. Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and fit mRNA expression in the rat thyroid in vivo. *J Clin Invest* 1995;95:1285-302.

159. Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid follicular cells. *Thyroid* 2006;15:389-97.

160. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cell lines. *Clin Cancer Res* 2006;12:1785-93.

161. Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. *Br J Cancer* 2005;92:1899-905.

162. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, HermseMJ, et al. Methylation of the PIK3CA gene in anaplastic thyroid cancer. *Cancer Res* 2005;65:1019-27.

163. Fagin JA. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cells and papillary thyroid cancer specimens. *Mutat Res* 2005;570:17-32.

164. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. *Thyroid* 2006;16:633-42.

165. De Gregorio G, Coppa A, Cosentino C, Ucci S, Messina S, Nicolosi A, et al. The p53 regulatory subunit of P3K mediates TSH-cAMP-PKA growth and survival signals. *Oncogene* 2007;26:1435-47.

166. De Falco V, Guarino V, Malorni L, Cirafici AM, Troglio F, Erren E, et al. RAII(ShcC/N-Shc)-dependent recruitment of RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary of the Gesellschaft für Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. *FEBS J* 2005;272:3491-504.

167. Vandeput F, Perpete P, Coulonval K, Lamy F, Dumont JE. Role of the different mitogen-activated protein kinase subfamilies in the stimulation of dog and human thyroid epithelial cell proliferation by cyclic adenosine 3’-monophosphate and growth factors. *Endocrinology* 2003;144:1341-9.

168. Mandai M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. *Br J Cancer* 2005;92:1899-905.

169. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, HermseMJ, et al. Methylation of the PIK3CA gene in anaplastic thyroid cancer. *Cancer Res* 2005;65:1019-27.

170. Fiski T, Foukakis T, Dwight T, Lundberg J, Hoag A, Wallin G, et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. *Genes Chromosomes Cancer* 2002;35:74-80.

171. Xing M. Gene methylation in thyroid tumorigenesis. *Endocrinology* 2007;148:948-53.

172. Puxeddé E, Zhao G, Stringer JR, Medvedovic M, Moretti S, Fagin JA. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. *Mutat Res* 2005;570:17-32.

173. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. *Thyroid* 2006;16:633-42.

174. Weng LP, Gimm O, Kum JB, Smith WM, Zhou XP, Wynford-Thomas D, et al. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. *Hum Mol Genet* 2001;10:251-8.

175. Lee IS, Hur EM, Suh BC, Kim MH, Koh DS, Rhee JU, et al. Protein kinase B- and C-induced insulin release from Ca2+-insensitive pools. *Cell Signal* 2003;15:529-37.

176. Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, et al. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell, and poorly differentiated human thyroid carcinoma. *Cancer Res* 1998;58:2063-6.

177. Kishihara K, Shimizu S, Chong J, Hishima T, Funata N, Kashigawa H, et al. Nuclear localization of immunoreactive β-catenin is specific to familial adenomatous polyposis in papillary thyroid carcinoma. *Jpn J Cancer Res* 2000;91:1160-2.

178. Garcia-Rostan G, Camp RL, Herrera A, Cancangui ML, Rimml DD, Tallini G. β-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. *Am J Pathol* 2001;158:987-96.

179. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. *Endocr Pathol* 2004;15:319-27.

180. Rocha AS, Soares P, Seruca R, Videla V, Matias-Guiu X, Cameselle-Teijeiro J, et al. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. *J Pathol* 2001;194:358-66.

181. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via β-arrestins in thyroid follicular cells. *Cell Signal* 2003;15:529-37.

182. Rocha AS, Soares P, Seruca R, Videla V, Matias-Guiu X, Cameselle-Teijeiro J, et al. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. *J Pathol* 2001;194:358-66.

183. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via β-arrestins in thyroid follicular cells. *Cell Signal* 2003;15:529-37.

184. Hino S, Tanji C, Nakayama KI, et al. Phosphorylation of β-catenin by cyclic adenosine 3’-monophosphate-dependent protein kinase A-independent mechanism. *Mol Pharmacol* 2001;60:924-33.
185. Rao AS, Kremenevskaja N, Resch J, Brabant G. Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/β-catenin signalling. *Eur J Endocrinol* 2005;153:929-38.

186. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant β-catenin expression. *Histopathology* 2005;47:248-56.

187. Nagayama Y, Shigematsu K, Namba H, Zeki K, Yamashita S, Niwa M. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. *Anticancer Res* 2000;20:2723-8.

188. Paron I, D’Ambrosio C, Scaloni A, Berlingieri MT, Pallante PL, Fusco A, et al. A differential proteomic approach to identify proteins associated with thyroid cell transformation. *J Mol Endocrinol* 2005;34:199-207.

189. de Capoa A, Grappelli C, Volpino P, Bononi M, Musolino A, Ciardi A, et al. Nuclear methylation levels in normal and cancerous thyroid cells. *Anticancer Res* 2004;24:1495-500.

190. Foukakis T, Au AY, Wallin G, Gei J, Forsberg L, Clifton-Bligh R, et al. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARγ fusion. *J Clin Endocrinol Metab* 2006;91:1143-9.

**Address for correspondence:**
Pilar Santisteban
Instituto de Investigaciones Biomédicas
CSIC-UAM
Arturo Duperier 4
28029 Madrid (Spain)
Fax: (3491) 585-4401
Email: psantisteban@iib.uam.es